Ginsenoside RG3 and cantharidin synergistically suppress the progression of hepatocellular carcinoma via targeting the PRMT1-SREBF1 axis-mediated lipid metabolism

作者
Yuehua Wang,Hengye Yuan,Yi Yu,Xianggang Gou,Z. Peter Wang,Zhongzheng Zhou,Zezhen Wang,Wei Yan,Haisheng Wang,Jia Yan
出处
期刊:Journal of Translational Medicine [BioMed Central]
卷期号:24 (1): 78-78 被引量:1
标识
DOI:10.1186/s12967-025-07550-8
摘要

BACKGROUND: Ginsenosides, such as ginsenoside RG3, demonstrate antitumor potential in hepatocellular carcinoma (HCC) and are often combined with cantharidin (CTD) in traditional Chinese medicine to achieve synergistic effects while mitigating CTD’s toxicity. However, the precise molecular mechanisms underlying this synergy remain elusive. METHODS: The progression of HCC was assessed using a series of in vitro assays, including CCK-8 for cell viability, EdU staining for proliferation, wound healing for migration, and transwell assay for invasion. The antitumor efficacy and hepatotoxicity were assessed in animal models using mice, employing tumor volume measurement, histopathological analysis, and quantification of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) through ELISA. To decipher the underlying synergistic mechanisms, we employed an integrated approach of network pharmacology, RNA sequencing, and molecular docking. The expression of key targets was verified by RT-qPCR and western blotting, while the direct interaction between PRMT1 and SREBF1 was confirmed by co-immunoprecipitation (Co-IP). RESULTS: The RG3/CTD combination exhibited a potent synergistic antitumor effect, suppressing tumor proliferation, migration, and invasion more effectively than either agent alone. Mechanistically, the therapy dually modulated aberrant lipid metabolism by concurrently inhibiting the PI3K/AKT/mTOR signaling axis and PRMT1-mediated epigenetic regulation. We identified a novel direct interaction between PRMT1 and SREBF1. The binding of the CTD/RG3 complex disrupted this interaction, inhibiting PRMT1-mediated arginine methylation of SREBF1 and consequently downregulating SREBF1 expression and activity. Furthermore, RG3 significantly mitigated CTD-induced hepatotoxicity by maintaining hepatic serum ALT and AST levels, an effect likely mediated by the modulation of AKT, ACOX1, and ABCB1 pathways to reduce oxidative stress and restore metabolic homeostasis. CONCLUSIONS: Our findings establish a novel RG3-CTD regimen that concurrently enhances therapeutic efficacy and reduces hepatotoxicity through coordinated targeting of oncogenic signaling and metabolic reprogramming. This study provides a robust mechanistic foundation for the clinical translation of RG3/CTD combination therapy for HCC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科研通AI2S的应助被Rainandbow采纳,获得10
1秒前
777发布了新的文献求助10
1秒前
1秒前
喜悦发布了新的文献求助10
1秒前
周钦完成签到,获得积分10
1秒前
熊一一完成签到,获得积分10
2秒前
葵辰完成签到 ,获得积分10
2秒前
NANO完成签到,获得积分10
2秒前
2秒前
八九发布了新的文献求助10
2秒前
重要白山发布了新的文献求助10
2秒前
3秒前
就爱吃抹茶完成签到 ,获得积分10
3秒前
嘟嘟完成签到,获得积分10
3秒前
闹闹的应助被科研通管家采纳,获得10
3秒前
残酷日光完成签到,获得积分10
3秒前
闹闹的应助被科研通管家采纳,获得10
3秒前
搜集达人的应助被科研通管家采纳,获得10
3秒前
吃米线的应助被科研通管家采纳,获得10
3秒前
思源的应助被淡然寇采纳,获得30
3秒前
fantasy的应助被科研通管家采纳,获得10
3秒前
顾矜的应助被科研通管家采纳,获得10
3秒前
Xin5599发布了新的文献求助10
3秒前
Maestro_S的应助被科研通管家采纳,获得30
4秒前
文刀完成签到,获得积分10
4秒前
领导范儿的应助被科研通管家采纳,获得10
4秒前
JamesPei的应助被科研通管家采纳,获得10
4秒前
Chauncey完成签到,获得积分10
4秒前
4秒前
丘比特的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
4秒前
chen发布了新的文献求助10
4秒前
上官若男的应助被科研通管家采纳,获得10
4秒前
打打的应助被科研通管家采纳,获得10
5秒前
完美世界的应助被科研通管家采纳,获得10
5秒前
5秒前
yurany完成签到,获得积分10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820